Oppenheimer Downgrades AN2 Therapeutics (ANTX) to Perform, 'see at best a two- to three-quarter delay to the Phase 3'
Tweet Send to a Friend
(Updated - February 12, 2024 10:42 AM EST)
Oppenheimer analyst Jeff Jones downgraded AN2 Therapeutics (NASDAQ: ANTX) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Jeff Jones downgraded AN2 Therapeutics (NASDAQ: ANTX) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
